Altimmune gains FDA breakthrough tag for MASH drug
Regulatory milestone accelerates development path as company plans 2026 Phase 3 trial for liver disease treatment
Altimmune's experimental liver disease drug pemvidutide has received the Food and Drug Administration's Breakthrough Therapy Designation, a regulatory milestone that positions the biotechnology company to accelerate development of what could become one of the first treatments for metabolic dysfunction-associated steatohepatitis, a progressive form of fatty liver disease.
The FDA granted the designation based on compelling 24-week data from the Phase 2b IMPACT trial, which showed statistically significant MASH resolution without worsening of fibrosis, alongside early and substantial improvements in liver fat and non-invasive markers of fibrosis and hepatic inflammation. The breakthrough status, announced on January 5, provides the Gaithersburg, Maryland-based company with more frequent FDA interactions and potential for accelerated approval pathways.
Altimmune plans to initiate a registrational Phase 3 trial in 2026, with trial design parameters now aligned with the FDA following an End-of-Phase 2 meeting in December. The trial will evaluate multiple pemvidutide doses over a 52-week treatment period with biopsy-based endpoints, the company disclosed in its fourth quarter earnings announcement.
The regulatory milestone follows positive 48-week data from the IMPACT trial announced in December, which demonstrated statistically significant improvements in key non-invasive markers of fibrosis across all treatment groups compared to placebo. The 1.2 mg and 1.8 mg doses achieved mean reductions from baseline in Enhanced Liver Fibrosis (ELF) scores of -0.49 and -0.58, respectively, compared to an increase of +0.16 in placebo-treated patients. For Liver Stiffness Measurement (LSM), the same doses resulted in mean reductions of -3.04 and -3.97, respectively, versus a minor reduction of -0.03 in the placebo group.
"The continued improvement in non-invasive fibrosis markers at 48 weeks, coupled with the favorable tolerability profile and weight loss, provides a strong foundation for advancing into Phase 3," said Vipin K. Garg, Altimmune's chief executive officer, in the company's press release.
Altimmune reported a net loss of $0.27 per share for the fourth quarter, slightly missing analyst estimates of -$0.26. Revenue totaled $26,000 for the three months ended December 31, 2025. The company's cash position strengthened significantly following financing activities in January 2026, including a $75 million registered direct offering and an additional $8 million raised through an at-the-market facility.
As of February 28, 2026, Altimmune held $340 million in cash and cash equivalents, up from $274 million at year-end 2025, providing sufficient runway to fund the planned Phase 3 trial through anticipated data readouts.
Despite these catalysts, Altimmune shares have declined 24 percent year-to-date, reflecting broader volatility in the biotechnology sector as investors rotate away from clinical-stage companies. The stock closed Wednesday at $4.27, giving the company a market capitalization of approximately $521 million. The shares remain well below their 52-week high of $7.73, though above the year's low of $2.90.
Analysts remain largely bullish on the stock, with a consensus price target of $17.67 representing more than 300 percent upside from current levels. The company maintains coverage from eight analysts, with three rating it a strong buy and five recommending it as a buy, according to market data.
The MASH market represents a significant untapped opportunity in biopharmaceuticals, with no FDA-approved treatments currently available for the progressive liver disease that affects millions of Americans and can lead to cirrhosis, liver failure, and the need for transplantation. Several competitors, including Madrigal Pharmaceuticals, are also advancing MASH candidates, though analysts point to pemvidutide's differentiated mechanism of action as a dual GLP-1/glucagon receptor agonist.
The Breakthrough Therapy Designation for pemvidutide "significantly de-risks the Phase 3 program and could shorten the development timeline," noted analysts at H.C. Wainwright in a recent research note, while also acknowledging that "execution risk remains, and MASH is a competitive landscape."
Investors will be watching closely for the initiation of the Phase 3 trial in the coming months, as well as potential partnership discussions that could help fund the expensive late-stage development program. The strengthened cash position and regulatory validation position Altimmune to advance its pipeline, though the path to commercialization in the competitive MASH market remains uncertain.